Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER B.V.
Autores
Citação
JTCVS OPEN, v.15, p.199-210, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Postoperative atrial fibrillation is the most common clinical complication after coronary artery bypass graft surgery. It is associated with a high risk of both stroke and death and increases the length of hospital stay and costs. This study aimed to evaluate anticoagulants in postoperative atrial fibrillation. Methods: A single-center, randomized, prospective, and open-label study. The trial was conducted in Heart Institute at University of São Paulo, Brazil. Patients who developed postoperative atrial fibrillation were randomized to anticoagulation with rivaroxaban or warfarin plus enoxaparin bridging. The primary objective was the cost-effectiveness evaluated by quality-adjusted life years, using the SF-6D questionnaire. The secondary end point was the combination of death, stroke, myocardial infarction, thromboembolic events, infections, bleeding, readmissions, and surgical reinterventions. The safety end point was any bleeding using the International Society on Thrombosis and Haemostasis score. Follow-up period was 30 days after hospital discharge. Results: We analyzed 324 patients and 53 patients were randomized. The median cost-effectiveness was $1423.20 in the warfarin group versus $586.80 in the rivaroxaban group (P = .002). The median cost was lower in the rivaroxaban group, $450.20 versus $947.30 (P < .001). The secondary outcome was similar in both groups, 44.4% in warfarin group versus 38.5% in the rivaroxaban group (P = .65). Bleeding occured in 25.9% in the warfarin group versus 11.5% in the rivaroxaban group (P = .18). Conclusions: Rivaroxaban was more cost-effective when compared with warfarin associated with enoxaparin bridging in postoperative atrial fibrillation after isolated coronary artery bypass grafting.
Palavras-chave
anticoagulation, coronary artery bypass surgery, cost-effective, costs, direct oral anticoagulant, postoperative atrial fibrillation
URI
https://observatorio.fm.usp.br/handle/OPI/58612
Referências
  1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomstrom-Lundqvist C., Et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS), Eur Heart J, 42, pp. 373-498, (2021)
  2. January C.T., Wann L.S., Calkins H., Field M.E., Chen L.Y., Furei K.L., Et al., 2019 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons, J Circulation, 140, pp. e125-e151, (2019)
  3. Gillinov A.M., Bagiella E., Moskowitz A.J., Raiten J.M., Groh M.A., Bowdish M.E., Et al., Rate control versus rhythm control for atrial fibrillation after cardiac surgery, N Engl J Med, 374, pp. 1911-1921, (2016)
  4. Frendl G.F., Sodickson A.C., Chung M.K., Waldo A.L., Gersh B.J., Tisdale J.E., Et al., 2014 AATS guidelines for the prevention and management of peri-operative atrial fibrillation and flutter (POAF) for thoracic surgical procedures, J Thorac Cardiovasc Surg, 148, pp. e153-e193, (2014)
  5. Dobrev D., Aguillar M., Heijman J., Guichard J.B., Nattel S., Postoperative atrial fibrillation: mechanisms, manifestations, and management, Nat Rev Cardiol, 16, pp. 417-436, (2019)
  6. Steinberg B.A., Zhao Y., He X., Fernandez A.F., Fullerton D.A., Thomaz K.L., Et al., Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry, Clin Cardiol, 37, pp. 7-13, (2014)
  7. Phan K., Ha H.S.K., Phan S., Medi C., Thomas S.P., Yan T.D., New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis, Eur J Cardio Thorac Surg, 48, pp. 817-824, (2015)
  8. Lin M.H., Kamel H., Singer D.E., Wu Y.L., Lee M., Ovbiagele B., Perioperative/postoperative atrial fibrillation and risk of subsequent stroke and/or mortality a meta-analysis, Stroke, 50, pp. 1364-1371, (2019)
  9. Saxena A., Dinh D.T., Smith J.A., Shardey G.C., Reid C.M., Newcomb A.E., Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients), Am J Cardiol, 109, pp. 219-252, (2012)
  10. El-Chami M.F., Kilgo P., Thourani V., Lattoulf O.M., Delurgio D.B., Guyton R.A., Et al., New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft, J Am Coll Cardiol, 55, pp. 1370-1376, (2010)
  11. Lapar D.J., Speier A.M., Crosby I.K., Fonner E., Brown M., Rich J.B., Et al., Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs, Ann Thorac Surg, 98, pp. 527-533, (2014)
  12. Anderson E., Johnke K., Leedahl D., Glogoza M., Newman R., Dyke C., Novel oral anticoagulants versus warfarin for the management of post-operative atrial fibrillation: clinical outcomes and cost analysis, Am J Surg, 210, pp. 1095-1102, (2015)
  13. Sezai A., Osaka S., Yaoita H., Arimoto M., Hata H., Tanaka M., Safety of the direct oral anticoagulant Edoxaban for atrial fibrillation after cardiac surgery: pilot study, J Atr Fibrillation, 9, (2016)
  14. Naik K.D., Whitson B.A., McLaughlin E.M., Matre N.B., Rozycki A.J., Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery, J Card Surg, 37, pp. 4740-4747, (2022)
  15. Sezai A., Taoka M., Osaka S., Kitazumi Y., Suzuki K., Kamata K., Et al., A comparative prospective observational study on the use of direct oral anticoagulants after cardiac surgery for the management of atrial fibrillation, Ann Thorac Cardiovasc Surg, 27, pp. 191-199, (2021)
  16. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Et al., 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes, Eur Heart J, 41, pp. 407-477, (2020)
  17. Campolina A.G., Bortoluzzo A.B., Ferraz M.B., Ciconelli R.M., The SF-6D Brazil questionnaire: generation models and applications in health economics, Rev Assoc Med Bras, 56, pp. 409-414, (2010)
  18. Cruz L.N., Camey S.A., Hoffmann J.F., Rowen D., Brazier J.E., Fleck M.P., Et al., Estimating the SF-6D value set for a population-based sample of Brazilians, Value Health, 14, pp. S108-S114, (2011)
  19. Scudeler T.L., Hueb W.A., Farkouh M.E., Maron D.J., Soarez P.C., Et al., Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: results from the MASS III trial, Int J Cardiol, 273, pp. 63-68, (2018)
  20. Russel L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C., The role of cost-effectiveness analysis in health and medicine, JAMA, 276, pp. 1172-1177, (1996)
  21. Brazier J., Roberts J., Deverill M., The estimation of a preference-based measure of health from the SF-36, J Health Econ, 21, pp. 271-292, (2002)
  22. Sousa-Uva M., Head S.J., Milojevic M., Collet J.P., Landoni G., Castella M., Et al., 2017 EACTS guidelines on perioperative medication in adult cardiac surgery, Eur J Cardio Thorac Surg, 53, pp. 5-33, (2018)
  23. Gaudino M., Benesch C., Bakaeen F., DeAnda A., Fremes S.E., Glance L., Et al., Considerations for reduction of risk of perioperative stroke in adult patients undergoing cardiac and thoracic aortic operations: a scientific statement from the American Heart Association, Circulation, 142, pp. e193-e209, (2020)
  24. Goyal P., Kim M., Krishnan U., Mccullough S.A., Cheung J.W., Kim L.K., Et al., Post-operative atrial fibrillation and risk of heart failure hospitalization, Eur Heart J, 43, pp. 2971-2980, (2022)
  25. Kosmidou I., Chen S., Kappetein P., Serruys P.W., Gersh B.J., Puskas J.D., Et al., New-onset atrial fibrillation after PCI or CABG for left main disease the EXCEL trial, J Am Coll Cardiol, 71, pp. 739-748, (2018)
  26. Aranki S.F., Shaw D.P., Adams D.H., Rizzo R.J., Cousper G.S., VanderVliet M., Et al., Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources, Circulation, 94, pp. 390-397, (1996)
  27. Ahlsson A., Fengsrud E., Bodin L., Englund A., Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality, Eur J Cardio Thorac Surg, 37, pp. 1353-1359, (2010)
  28. Lowres N., Mulcahy G., Jin K., Gallagher R., Neubeck L., Freedman B., Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis, Interact Cardiovasc Thorac Surg, 26, pp. 504-511, (2018)
  29. Mair H., Jilek C., Haas B., Lamm P., Ticagrelor and rivaroxaban elimination with Cytosorb Adsorber before urgent off-pump coronary bypass, Ann Thorac Surg, 110, pp. e369-e370, (2020)
  30. Connolly S.J., Crowther M., Eikelboom J.W., Gibson M., Curnutte J.T., Et al., Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors, N Engl J Med, 380, pp. 1326-1335, (2019)

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - ODS/03